Incannex announces appointment of dr. lou barbato as chief medical officer

New york and melbourne, australia, oct. 24, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of lou barbato, m.d., as chief medical officer (cmo) effective immediately. dr. barbato's drug development experience includes senior clinical development and operational roles at jazz pharmaceuticals, abbvie, biogen, novartis, and solvay. he joins incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.
IXHL Ratings Summary
IXHL Quant Ranking